These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 30732646)
1. Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation. Lee SE; Lim JY; Kim TW; Ryu DB; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min CK J Immunother Cancer; 2019 Feb; 7(1):35. PubMed ID: 30732646 [TBL] [Abstract][Full Text] [Related]
2. Myeloma-Secreted Galectin-1 Potently Interacts with CD304 on Monocytic Myeloid-Derived Suppressor Cells. Lim JY; Kim TW; Ryu DB; Park SS; Lee SE; Kim BS; Min CK Cancer Immunol Res; 2021 May; 9(5):503-513. PubMed ID: 33771821 [TBL] [Abstract][Full Text] [Related]
4. Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma. Wichert S; Pettersson Å; Hellmark T; Johansson Å; Hansson M Exp Hematol; 2016 May; 44(5):342-351.e5. PubMed ID: 26774385 [TBL] [Abstract][Full Text] [Related]
5. Decidua-derived granulocyte macrophage colony-stimulating factor induces polymorphonuclear myeloid-derived suppressor cells from circulating CD15+ neutrophils. Li C; Chen C; Kang X; Zhang X; Sun S; Guo F; Wang Q; Kou X; Bai W; Zhao A Hum Reprod; 2020 Dec; 35(12):2677-2691. PubMed ID: 33067638 [TBL] [Abstract][Full Text] [Related]
6. CD33 Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700 [TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients. Jordan KR; Kapoor P; Spongberg E; Tobin RP; Gao D; Borges VF; McCarter MD Cancer Immunol Immunother; 2017 Apr; 66(4):503-513. PubMed ID: 28108766 [TBL] [Abstract][Full Text] [Related]
8. Decreased circulating myeloid-derived suppressor cell count at the engraftment is one of the risk factors for multiple myeloma relapse after autologous hematopoietic stem cell transplantation. Tyrinova T; Batorov E; Aristova T; Ushakova G; Sizikova S; Denisova V; Chernykh E Heliyon; 2024 Mar; 10(5):e26362. PubMed ID: 38434301 [TBL] [Abstract][Full Text] [Related]
9. The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. Rodríguez-Lobato LG; Martínez-Roca A; Castaño-Díez S; Palomino-Mosquera A; Gutiérrez-García G; Pedraza A; Suárez-Lledó M; Rovira M; Martínez C; Fernández de Larrea C; Cibeira MT; Rosiñol L; Lozano E; Marín P; Cid J; Lozano M; Moreno-Castaño AB; Palomo M; Díaz-Ricart M; Gallego C; Hernando A; Segura S; Carreras E; Urbano-Ispizua Á; Bladé J; Fernández-Avilés F PLoS One; 2020; 15(11):e0241778. PubMed ID: 33147257 [TBL] [Abstract][Full Text] [Related]
10. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential. Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030 [TBL] [Abstract][Full Text] [Related]
11. Early Expansion of Circulating Granulocytic Myeloid-derived Suppressor Cells Predicts Development of Nosocomial Infections in Patients with Sepsis. Uhel F; Azzaoui I; Grégoire M; Pangault C; Dulong J; Tadié JM; Gacouin A; Camus C; Cynober L; Fest T; Le Tulzo Y; Roussel M; Tarte K Am J Respir Crit Care Med; 2017 Aug; 196(3):315-327. PubMed ID: 28146645 [TBL] [Abstract][Full Text] [Related]
12. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670 [TBL] [Abstract][Full Text] [Related]
13. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. Garfall AL; Stadtmauer EA; Hwang WT; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV; Dhodapkar K; Das R; Vogl DT; Weiss BM; Cohen AD; Mangan PA; Ayers EC; Nunez-Cruz S; Kulikovskaya I; Davis MM; Lamontagne A; Dengel K; Kerr ND; Young RM; Siegel DL; Levine BL; Milone MC; Maus MV; June CH JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669947 [TBL] [Abstract][Full Text] [Related]
14. Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Favaloro J; Liyadipitiya T; Brown R; Yang S; Suen H; Woodland N; Nassif N; Hart D; Fromm P; Weatherburn C; Gibson J; Ho PJ; Joshua D Leuk Lymphoma; 2014 Dec; 55(12):2893-900. PubMed ID: 24625328 [TBL] [Abstract][Full Text] [Related]
15. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251 [TBL] [Abstract][Full Text] [Related]
16. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation. Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157 [TBL] [Abstract][Full Text] [Related]
17. Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients. Wang Z; Zhang L; Wang H; Xiong S; Li Y; Tao Q; Xiao W; Qin H; Wang Y; Zhai Z Cancer Immunol Immunother; 2015 Mar; 64(3):389-99. PubMed ID: 25548095 [TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive role of CD11b Hyun SY; Na EJ; Jang JE; Chung H; Kim SJ; Kim JS; Kong JH; Shim KY; Lee JI; Min YH; Cheong JW Cancer Med; 2020 Oct; 9(19):7007-7017. PubMed ID: 32780544 [TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Mougiakakos D; Jitschin R; von Bahr L; Poschke I; Gary R; Sundberg B; Gerbitz A; Ljungman P; Le Blanc K Leukemia; 2013 Feb; 27(2):377-88. PubMed ID: 22828446 [TBL] [Abstract][Full Text] [Related]
20. Expression of Inhibitory Molecules (Arginase-1, IDO, and PD-L1) by Myeloid-Derived Suppressor Cells in Multiple Myeloma Patients in Remission. Tyrinova TV; Batorov EV; Aristova TA; Ushakova GY; Sizikova SA; Denisova VV; Ostanin AA; Chernykh ER Bull Exp Biol Med; 2022 Nov; 174(1):71-75. PubMed ID: 36437327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]